53 related articles for article (PubMed ID: 38468814)
21. CSE1L silencing impairs tumor progression via MET/STAT3/PD-L1 signaling in lung cancer.
Liu W; Zhou Z; Li Y; Xu J; Shen Y; Luo S; Zhou Y; Wu X; Zhao H; Beer DG; He Y; Chen G
Am J Cancer Res; 2021; 11(9):4380-4393. PubMed ID: 34659893
[TBL] [Abstract][Full Text] [Related]
22. Non-small-cell lung cancer classification via RNA-Seq and histology imaging probability fusion.
Carrillo-Perez F; Morales JC; Castillo-Secilla D; Molina-Castro Y; Guillén A; Rojas I; Herrera LJ
BMC Bioinformatics; 2021 Sep; 22(1):454. PubMed ID: 34551733
[TBL] [Abstract][Full Text] [Related]
23. Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma.
Al-Odat O; von Suskil M; Chitren R; Elbezanti W; Srivastava S; Budak-Alpddogan T; Jonnalagadda S; Aggarwal B; Pandey M
Front Pharmacol; 2021; 12():699629. PubMed ID: 34349655
[TBL] [Abstract][Full Text] [Related]
24. Myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy.
Mittal P; Singh S; Sinha R; Shrivastava A; Singh A; Singh IK
Int J Biol Macromol; 2021 Sep; 187():999-1018. PubMed ID: 34339789
[TBL] [Abstract][Full Text] [Related]
25. Knockdown of miR-15b partially reverses the cisplatin resistance of NSCLC through the GSK-3β/MCL-1 pathway.
Lu T; Lu W; Jia C; Lou S; Zhang Y
Adv Clin Exp Med; 2021 Aug; 30(8):849-857. PubMed ID: 34286518
[TBL] [Abstract][Full Text] [Related]
26. Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
Li D; Chi Y; Chen X; Ge M; Zhang Y; Guo Z; Wang J; Chen J; Zhang J; Cheng Y; Li Z; Liu H; Qin J; Zhu J; Cheng R; Xu Z; Zheng X; Tang P; Gao M
Clin Cancer Res; 2021 Jul; 27(13):3567-3575. PubMed ID: 33832949
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study.
Wang P; Fang X; Yin T; Tian H; Yu J; Teng F
Front Oncol; 2021; 11():628124. PubMed ID: 33791214
[TBL] [Abstract][Full Text] [Related]
28. Anlotinib suppresses metastasis and multidrug resistance
Yan LH; Zhang D; Mo SS; Yuan H; Mo XW; Zhao JM
J Cancer; 2021; 12(7):2092-2104. PubMed ID: 33754008
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of resistance to chemotherapy in non-small cell lung cancer.
Min HY; Lee HY
Arch Pharm Res; 2021 Feb; 44(2):146-164. PubMed ID: 33608812
[TBL] [Abstract][Full Text] [Related]
30. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
[TBL] [Abstract][Full Text] [Related]
31. Anlotinib as a promising inhibitor on tumor growth of oral squamous cell carcinoma through cell apoptosis and mitotic catastrophe.
Deng Z; Liao W; Wei W; Zhong G; He C; Zhang H; Liu Q; Xu X; Liang J; Liu Z
Cancer Cell Int; 2021 Jan; 21(1):37. PubMed ID: 33422069
[TBL] [Abstract][Full Text] [Related]
32. High expression of MYEOV reflects poor prognosis in non-small cell lung cancer.
Zhang R; Ma A
Gene; 2021 Feb; 770():145337. PubMed ID: 33278551
[TBL] [Abstract][Full Text] [Related]
33. NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted Therapy.
Haratake N; Seto T
Clin Lung Cancer; 2021 Jan; 22(1):1-5. PubMed ID: 33272813
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA216b mediated downregulation of HSP27/STAT3/AKT signaling is critically involved in lambertianic acid induced apoptosis in human cervical cancers.
Lee JC; Sim DY; Lee HJ; Im E; Choi JB; Park JE; Park WY; Jung JH; Shim BS; Kim SH
Phytother Res; 2021 Feb; 35(2):898-907. PubMed ID: 32822082
[TBL] [Abstract][Full Text] [Related]
35. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
Sun C; Gao W; Liu J; Cheng H; Hao J
Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129
[TBL] [Abstract][Full Text] [Related]
36. Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer.
Song X; Shen L; Tong J; Kuang C; Zeng S; Schoen RE; Yu J; Pei H; Zhang L
Theranostics; 2020; 10(18):8098-8110. PubMed ID: 32724460
[TBL] [Abstract][Full Text] [Related]
37. Targeting
Recondo G; Che J; Jänne PA; Awad MM
Cancer Discov; 2020 Jul; 10(7):922-934. PubMed ID: 32532746
[TBL] [Abstract][Full Text] [Related]
38. Circular RNA circBFAR promotes the progression of pancreatic ductal adenocarcinoma via the miR-34b-5p/MET/Akt axis.
Guo X; Zhou Q; Su D; Luo Y; Fu Z; Huang L; Li Z; Jiang D; Kong Y; Li Z; Chen R; Chen C
Mol Cancer; 2020 May; 19(1):83. PubMed ID: 32375768
[TBL] [Abstract][Full Text] [Related]
39. Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights.
Meador CB; Hata AN
Pharmacol Ther; 2020 Jun; 210():107522. PubMed ID: 32151666
[TBL] [Abstract][Full Text] [Related]
40. IGF1R facilitates epithelial-mesenchymal transition and cancer stem cell properties in neuroblastoma via the STAT3/AKT axis.
Wang XH; Wu HY; Gao J; Wang XH; Gao TH; Zhang SF
Cancer Manag Res; 2019; 11():5459-5472. PubMed ID: 31354352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
